07 Aug 07
Merckâ€™s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies â€“ Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this yearâ€™s American Diabetes Association meeting in Chicago.
Olwen Glynn Owen
25 Jul 07
Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007
second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to
$5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half.
Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7%
for the 2007 second quarter and 8% for the 2007 first half.
20 Jul 07
First medicine shown to extend survival of previously untreated lung cancer patients beyond one year.
02 Jul 07
Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Clientâ€™s needs throughout Europe. Dan Barrington, Director, said â€œâ€¦we are delighted Tony agreed to join Barrington James Limited, he brings
11 Jun 07
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncologyâ€™s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen
08 Jun 07
Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the studyâ€™s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen
05 Jun 07
In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
04 Jun 07
Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this yearâ€™s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen
23 May 07
In todayâ€™s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
22 May 07
With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe thatâ€™s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
14 May 07
Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play itâ€™s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
23 Apr 07
The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the â€˜twilight zoneâ€™ of type 2 diabetes care.
03 Apr 07
Over the decade, the art of copying and stealing other people's content and ideas has settled
comfortably in the mainstream across the globe. What formerly would constitute an act of piracy
is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
20 Mar 07
Covering all the major topics surrounding EDC and other e-Clinical technologies, this yearâ€™s e-Clinical Trials event will also look carefully at how to integrate a range of systems for a successful e-Clinical programme and bring you up-to-date on current standards and the latest technological options. Delegates will also benefit from a highly detailed interactive workshop on managing e-Clinical Trials in exotic and difficult locations.
Furthermore, This yearâ€™s e-Clinical Trials conference wil
30 Jan 07
Suddenly, there is a new global tidal wave of change all over the Asian region, the obvious signs are people on the move, new developments and properties popping up all over the region and a nouvo-consumerism is appearing at every corner, customers are buying shiny and wonderful things with beautiful packaging and companies are addressing their hunger with massive blitzes. ...
30 Jan 07
Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Olwen Glynn Owen
03 Jan 07
Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III
Olwen Glynn Owen
15 Dec 06
With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers.
12 Dec 06
Frost & Sullivan, along with their panel of distinguished industry experts, will take a look at the changing dynamics in today's U.S. pharmaceutical industry. The panel will review traditional adherence programs, examine what is and is not working, and what the next steps are toward addressing the multiple barriers contributing to non-adherence.
For additional information, please visit http://ebroadcast.frost.com/loyalty
08 Dec 06
Despite almost 200 million people suffering from high blood pressure in the western world alone, the growth rate of the antihypertensive market is actually slowing, largely as a result of generic incursion. In fact many pharmaceutical companies, including those with strong cardiovascular portfolios, are turning their back on this market in favor of more profitable indications, such as oncology.
24 Nov 06
AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry.
21 Nov 06
Inhalabe insulin treatments promised to revolutionize the treatment of insulin-dependent diabetes by removing the 'injection barrier' from treatment regimes. However, while inhalable insulins will see a reasonable level of uptake, they aren't the sure fire blockbuster they were hyped to be.
10 Nov 06
The treatment of asthma and COPD has dramatically improved following the increased use of fixed dose inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination therapies. Although Advair dominates the total asthma/COPD market, Symbicort's recent US approval and Chiesi's recent European approval of an ICS/LABA combination drug, signal a major change in the market dynamics.
31 Oct 06
The success of neuropathic pain drug Neurontin earned Pfizer its reputation as the "neuropathic pain company" and the US pharmaceutical giant faced very little competition in a relatively untapped market for ten years. Neuropathic pain is now one of the most attractive indications in the pharmaceutical industry but Pfizer still dominates the market.
20 Oct 06
While there have been no new treatments approved for systemic lupus erythematosus (SLE) in almost 40 years, there are some promising treatments currently in the development pipeline. Unfortunately, the ambiguity surrounding the requirements of clinical trials is preventing these drugs from being approved. However, faced with few alternatives, that hasn't prevented physicians using them off-label.